- Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
- Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
- Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
- Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
- Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
- Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
- Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
- Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
- Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
- Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
More ▼
Key statistics
On Friday, Beam Therapeutics Inc (BEAM:NSQ) closed at 23.08, 36.17% above the 52 week low of 16.95 set on Oct 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.44 |
---|---|
High | 23.44 |
Low | 22.63 |
Bid | 22.70 |
Offer | 23.75 |
Previous close | 23.48 |
Average volume | 1.48m |
---|---|
Shares outstanding | 82.31m |
Free float | 81.12m |
P/E (TTM) | -- |
Market cap | 1.93bn USD |
EPS (TTM) | -1.74 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼